Zhao JN, Fan Y, Wu SD. Liver injury in COVID-19: A minireview. World J Clin Cases 2020; 8(19): 4303-4310 [PMID: 33083389 DOI: 10.12998/wjcc.v8.i19.4303]
Corresponding Author of This Article
Ying Fan, MD, PhD, Doctor, Professor, Department of General Surgery, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. coolingpine78@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 6, 2020; 8(19): 4303-4310 Published online Oct 6, 2020. doi: 10.12998/wjcc.v8.i19.4303
Liver injury in COVID-19: A minireview
Jian-Nan Zhao, Ying Fan, Shuo-Dong Wu
Jian-Nan Zhao, Ying Fan, Shuo-Dong Wu, Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning Province, China
Author contributions: Zhao JN drafted and revised the manuscript; Fan Y and Wu SD reviewed and revised the manuscript; All authors read and approved the final version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Ying Fan, MD, PhD, Doctor, Professor, Department of General Surgery, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang 110004, Liaoning Province, China. coolingpine78@163.com
Received: April 30, 2020 Peer-review started: April 30, 2020 First decision: May 21, 2020 Revised: June 1, 2020 Accepted: September 8, 2020 Article in press: September 8, 2020 Published online: October 6, 2020 Processing time: 150 Days and 17.5 Hours
Core Tip
Core Tip: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Liver injury was observed in COVID-19 patients especially in severe and critical types. Liver injury presented differentially based on disease severity, geographical areas, and patient age. It may be related to systemic inflammatory response, immune damage, ischemia-reperfusion injury, viral direct damage, drug induce, mechanical ventilation, and underlying diseases. Special treatment is unnecessary in most mild liver injury cases and only one or two types of hepatoprotective drugs should be used to treat significant liver injury. Monitoring liver function is important parameter during the treatment of COVID-19 as it affects survival and recovery of patients, and its significance should be emphasized for doctors treating the disease.
